<DOC>
	<DOCNO>NCT00386607</DOCNO>
	<brief_summary>Assessment long-term safety tolerability combination aliskiren valsartan ( 300 mg/ 320 mg ) patient high blood pressure , follow assessment long-term safety tolerability combination aliskiren/valsartan/Hydrochlorothiazide ( HCTZ ) .</brief_summary>
	<brief_title>A Safety Tolerability Study Combination Aliskiren/Valsartan Patients With High Blood Pressure , Followed Long-term Safety Tolerability Aliskiren , Valsartan Hydrochlorothiazide .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Male female outpatient 18 year age old . For newly diagnosed/untreated patient essential hypertension define msDBP ≥ 90 &lt; 110 mmHg Visit 1 Visit 4 For previously treat patient essential hypertension define msDBP ≥ 90 &lt; 110 mmHg 2 4 week washout ( Visit 4 ) Patients eligible able participate study consent purpose nature investigation clearly explain ( write inform consent ) . Severe hypertension ( msDBP ≥ 110 mmHg and/or msSBP ≥ 180 mmHg ) Women childbearing potential , unless meet definition postmenopausal use acceptable method contraception . History evidence secondary form hypertension . History hypertensive encephalopathy cerebrovascular accident . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hypertension , aliskiren , valsartan , HCTZ , blood pressure</keyword>
</DOC>